IP Library Granted Patent US 6,929,805
Granted Patent B2
US 6,929,805 · App. 09/402,737 · Granted Aug 16, 2005

Analgesic combination

Assignee: Bayer Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,929,805
App. No.
09/402,737
Granted
Aug 16, 2005
Kind
B2
Abstract

The present invention relates to medicinal preparations which can be administered orally and contain a fixed combination of at least one locally acting analgesic with a rapid onset of action and at least one systemically acting analgesic with a sustained action.

Claims (40)

1. A preparation which can be administered orally and contains a fixed combination of at least one locally acting analgesic with a rapid onset of action (element A) with at least one systemically acting analgesic with a sustained action (element B), wherein element A and element B provide distinct active analgesic compounds.

2. A preparation according to claim 1 , characterized in that the active substance employed as element A shows an optimal duration of action of from 0.5 to 120 minutes, and the active substance employed as element B has an action of from 15 minutes up to 24 hours.

3. A preparation according to claim 1 , characterized in that elements A and B are selected so that the fixed combination has a duration of action of from 2 minutes up to 12 hours.

4. Process for producing a preparation according to claim 1 , characterized in that the fixed combination of an active substance of element A and an active substance of element B are converted together with conventional ancillary substances and carrier into a suitable administration form.

5. The preparation according to claim 1 , which is in the form of a press-coated tablet.

6. The preparation according to claim 1 , which is in the form of coated pastille.

7. The preparation according to claim 1 , which is in the form of a chewing gum.

8. The preparation according to claim 1 , which is in the form of a hard caramel with a liquid, semisolid or solid core.

9. The preparation according to claim 1 , which is in the form of a inner core tablet coated with an outer coating, wherein the outer coating comprises the at least one locally acting analgesic with a rapid onset of action (element A), the inner core tablet comprises the at least one systemically acting analgesic with a sustained action (element B), and wherein elements A and B are provide distinct active analgesic compounds.

10. A preparation which can be administered orally and is in the form of a inner core tablet coated with an outer coating, wherein the outer coating comprises at least one locally acting analgesic with a rapid onset of action (element A) selected from the group consisting of benzocaine, amethocaine, amylocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, chlormecaine, cyclomethycaine, isobutamben, meprylcaine, oxybuprocaine, procaine, propipocaine, proxymetacine, tricaine, lidocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, oxethazaine, prilocaine, ropivacaine, ethyl p-piperidinoacetyl-aminobenzoate, tolycaine, trimecaine and vadocaine, and the inner core tablet comprises at least one systemically acting analgesic with a sustained action (element B) selected from the group consisting of aceclofenac, alclofenac, bromofenac, diclofenac, fenclofenac, acemetacin, amfenac sodium, bendazac, glucametacin, oxametacin, acetanilide, alminoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozin, acetyl salicylic acid, salts of acetylsalicylic acid, diflunisal, etersalate, fosfosal, salol, salsalate, salacetamide, amidopyrine, dipyrone, droxicam, isoxicam, piroxicam, azapropazone, bumadizone calcium, oxyphenbutazone, etodolac, galfenine, sodium meclofenamate, mefenamic acid, momiflumate, idomethacin, paracetamol, paracetamol derivatives, anirolac, benzpiperylone, benzydamine hydrochloride, sodium butibufen, chlorthenoxazine, cinmetacin, clonixin, cloracetadol, difenpiramide, diproqualone, etenzamide, famprofazone, flupirtine maleate, ibuproxam, indoprofen, isamfazone, meloxicam, metiazinic acid, metifenazone, nifenazone, niflumic, mimesulide, pirazolac, pranoprofen, proquazone, protizinic acid and ramifenazone.

11. The preparation according to claim 10 , which is in the form of an inner core tablet coated with an outer coating, wherein the outer coating comprises benzocaine as the at least one locally acting analgesic with a rapid onset of action (element A), and the inner core tablet comprises acetylsalicylic acid or salt thereof as the at least one systemically acting analgesic with a sustained action (element B).

12. A method of alleviating pain in a patient in need thereof comprising administering to said patient a preparation according to claim 1 .

13. A preparation which can be administered orally and contains a fixed combination of at least one locally acting analgesic with a rapid onset of action (element A) with at least one systemically acting analgesic with a sustained action (element B), wherein element A and element B provide distinct active analgesic compounds, and the preparation is formulated such that element A is released from the preparation before element B upon oral administration.

14. A method of alleviating pain in a patient in need thereof comprising administering to said patient a preparation according to claim 10 .

15. A method of alleviating pain in a patient in need thereof comprising administering to said patient a preparation according to claim 13 .

16. An analgesic preparation comprising,

a) element A, which comprises at least one locally acting analgesic having a rapid onset of action,

b) element B, which comprises a core tablet having at least one systemically acting analgesic having sustained action,

and wherein element A is a coating that encloses at least a portion of said core tablet's surface area and wherein element A and element B provide distinct active analgesic compounds.

17. The analgesic preparation of claim 16 , wherein element A entirely encloses element B.

18. The analgesic preparation of claim 16 , wherein element A encloses less than 100% of element B's surface area.

19. The analgesic preparation of claim 16 , wherein the at least one locally acting analgesic is selected from the group consisting of benzocaine, amethocaine, amylocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, chlormecaine, cyclomethycaine, isobutamben, meprylcaine, oxybuprocaine, procaine, propipocaine, proxymetacine, tricaine, lidocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, oxethazaine, prilocaine, ropivacaine, ethyl p-piperidinoacetyl-aminobenzoate, tolycaine, trimecaine and vadocaine.

20. The analgesic preparation of claim 16 , wherein the at least one systemically acting analgesic having sustained action, is selected from the group consisting of aceclofenac, alclofenac, bromofenac, diclofenac, fenclofenac, acemetacin, amfenac sodium, bendazac, glucametacin, oxametacin, acetanilide, alminoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozin, acetyl salicylic acid, salts of acetylsalicylic acid, diflunisal, etersalate, fosfosal, salol, salsalate, salacetamide, amidopyrine, dipyrone, droxicam, isoxicam, piroxicam, azapropazone, bumadizone calcium, oxyphenbutazone, etodolac, galfenine, sodium meclofenamate, mefenamic acid, morniflumate, idomethacin, paracetamol, paracetamol derivatives, anirolac, benzpiperylone, benzydamine hydrochloride, sodium butibufen, chlorthenoxazine, cinmetacin, clonixin, cloracetadol, difenpiramide, diproqualone, etenzamide, famprofazone, flupirtine maleate, ibuproxam, indoprofen, isamfazone, meloxicam metiazinic acid, metifenazone, nifenazone, niflumic acid, mimesulide, pirazolac, pranoprofen, proquazone, protizinic acid and ramifenazone.

21. An analgesic preparation comprising an element A and an element B, wherein,

a) element A comprises at least one locally acting analgesic having a rapid onset of action, said at least one locally acting analgesic being selected from the group consisting of benzocaine, amethocaine, amylocaine, butacaine, butoxycaine, butyl aminobenzoate, chloroprocaine, chlormecaine, cyclomethycaine, isobutamben, meprylcaine, oxybuprocaine, procaine, propipocaine, proxymetacine, tricaine, lidocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine, etidocaine, mepivacaine, oxethazaine, prilocaine, ropivacaine, ethyl p-piperidinoacetyl-aminobenzoate, tolycaine, trimecaine and vadocaine; and

b) element B comprises at least one systemically acting analgesic having sustained action, and wherein the locally acting analgesic having a rapid onset of action that comprises element A is an analgesic different from the analgesic in element B.

22. An analgesic preparation comprising an element A and an element B, wherein,

a) element A comprises at least one locally acting analgesic having a rapid onset of action; and

b) element B comprises at least one systemically acting analgesic having sustained action, wherein said at least one systemically acting analgesic is selected from the group consisting of aceclofenac, alclofenac, bromofenac, diclofenac, fenclofenac, acemetacin, amfenac sodium, bendazac, glucametacin, oxametacin, acetanilide, alminoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, oxaprozin, acetyl salicylic acid, salts of acetylsalicylic acid, diflunisal, etersalate, fosfosal, salol, salsalate, salacetamide, amidopyrine, dipyrone, droxicam, isoxicam, piroxicam, azapropazone, bumadizone calcium, oxyphenbutazone, etodolac, galfenine, sodium meclofenamate, mefenamic acid, morniflumate, idomethacin, paracetamol, paracetamol derivatives, anirolac, benzpiperylone, benzydamine hydrochloride, sodium butibufen, chlorthenoxazine, cinmetacin, clonixin, cloracetadol, difenpiramide, diproqualone, etenzamide, famprofazone, flupirtine maleate, ibuproxam, indoprofen, isamfazone, meloxicam, metiazinic acid, metifenazone, nifenazone, niflumic acid, mimesulide, pirazolac, pranoprofen, proquazone, protizinic acid and ramifenazone, and wherein element A and element B provide distinct active analgesic compounds.

23. An analgesic preparation comprising,

a) element A, which further comprises at least one locally acting analgesic having a rapid onset of action,

b) element B, which further comprises at least one systemically acting analgesic having sustained action,

and wherein element A and element B provide distinct active analgesic compounds, and are each independently provided in said preparation in a manner that resist commingling of said element A and element B until administration of said preparation to a subject.

24. The analgesic preparation of claim 23 , wherein the preparation is a chewable gum or chewable candy that further comprises at least one distinct region having element A, and at least one distinct region having element B, and wherein said regions do not commingle prior to administering said preparation to a subject.

25. The analgesic preparation according to claim 23 , wherein the preparation is a solid form of candy, having a liquid center.

26. The analgesic preparation of claim 24 , wherein the regions are juxtaposed in a pattern of bar-shaped stripes.

27. The analgesic preparation of claim 24 , wherein the regions comprising each of said element A or B, further comprise layers, stacked one on top of the other.

28. A preparation that can be administered orally and comprises a fixed combination of at least one locally acting ester-type anesthetic having a rapid onset of action (element A), and further comprising at least one systemically acting analgesic with a sustained action (element B), wherein,

(i) element A and element B provide distinct active analgesic compounds, and

(ii) element A comprises an outer coating that envelopes a core tablet comprising element B.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2016
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 039756/0128 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2009
From: BAYER AKTIENGESELLSCHAFT
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023525/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 1999
From: NEUSER, DIETER; FIERUS, MONIKA; WIEHL, WOLFGANG
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 010409/0084 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 1999
From: NEUSER, DIETER; FIERUS, MONIKA; WIEHL, WOLFGANG
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 010633/0974 →
Priority Claims (1)
DE 197 15 594 · Apr 15, 1997 · national
Continuity (1)
Related Publication 20010002999A1 · Jun 7, 2001